Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Nuvalent Inc.

In a report released today, from Jefferies reiterated a Buy rating on Nuvalent, with a price target of $164.00. In addition to Jefferies, Nuvalent ...

Jefferies Keeps Their Buy Rating on Nuvalent (NUVL)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tilray (TLRY – Research Report) and Nuvalent (NUVL – Research Rep...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tilray (TLRY) and Nuvalent (NUVL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nuvalent (NUVL – Research Report), Carlsmed, Inc. (C...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Disc Medicine (IRON – Research Report), Nuvalent (...

Market Cap	$6.70B	P/E Ratio	N/A
52W High	$113.02	52W Low	$55.54
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	86.0%
Overall Score	45	Value Score	40
Quality Score	42	Technical Score	54

EPS Current Est	$-5.68	EPS Next Est	$-5.93
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NUVL	$104.95	+2.00%	500.47K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NUVL	$104.95	+2.0%	500.47K
3
4
5
6

NUVL

NUVL

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Nuvalent Inc. Data in Excel

Get Nuvalent Inc. Data in Excel